These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36261044)

  • 21. The ethics of gene therapy for hemophilia: a narrative review.
    Baas L; van der Graaf R; van Hoorn ES; Bredenoord AL; Meijer K;
    J Thromb Haemost; 2023 Mar; 21(3):413-420. PubMed ID: 36696181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revocation of the conditional marketing authorisation of a cancer medicine: The olaratumab experience.
    Herold R; Camarero J; Melchiorri D; Sebris Z; Enzmann H; Pignatti F
    Eur J Cancer; 2019 Dec; 123():25-27. PubMed ID: 31655357
    [No Abstract]   [Full Text] [Related]  

  • 23. The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines.
    Cavaleri M; Enzmann H; Straus S; Cooke E
    Lancet; 2021 Jan; 397(10272):355-357. PubMed ID: 33453149
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union.
    Jokura Y; Yano K; Yamato M
    J Tissue Eng Regen Med; 2018 Feb; 12(2):e1056-e1062. PubMed ID: 28211195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valoctocogene Roxaparvovec: First Approval.
    Blair HA
    Drugs; 2022 Sep; 82(14):1505-1510. PubMed ID: 36214970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A.
    Hemşinlioğlu C; Aslan ES; Taştan C; Çakırsoy D; Turan RD; Seyis U; Elek M; Sır Karakuş G; Günaydın ÖS; Abanuz S; Kançağı DD; Yurtsever B; Yalçın K; Kasap M; Ovalı E
    Turk J Haematol; 2023 May; 40(2):118-124. PubMed ID: 37022209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemophilia as a blueprint for gene therapy.
    Ragni MV
    Science; 2021 Oct; 374(6563):40-41. PubMed ID: 34591611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recent advance in hemophilia therapy (2): gene and cell therapy for hemophilia].
    Ohmori T; Mizukami H; Madoiwa S; Ozawa K; Sakata Y
    Rinsho Ketsueki; 2014 Aug; 55(8):899-907. PubMed ID: 25186479
    [No Abstract]   [Full Text] [Related]  

  • 29. Measuring success in hemophilia gene therapy using a factor level & outcomes yardstick.
    Machin N; Ragni MV
    Expert Rev Hematol; 2018 Feb; 11(2):83-86. PubMed ID: 29300108
    [No Abstract]   [Full Text] [Related]  

  • 30. Advances in Gene Therapy for Hemophilia.
    Nathwani AC; Davidoff AM; Tuddenham EGD
    Hum Gene Ther; 2017 Nov; 28(11):1004-1012. PubMed ID: 28835123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Application for marketing authorization accepted for the the treatment of adult diabetes].
    Solignac M
    Soins; 2013 Jun; (776):8. PubMed ID: 23878876
    [No Abstract]   [Full Text] [Related]  

  • 32. Pediatric requirements in Europe stymie help for hemophilia.
    Peyvandi F; Rosendaal FR; O'Mahony B; Mannuccio Mannucci P
    Nat Med; 2014 Feb; 20(2):117. PubMed ID: 24504399
    [No Abstract]   [Full Text] [Related]  

  • 33. Hemophilia Gene Therapy: New Development from Bench to Bed Side.
    Guo XL; Chung TH; Qin Y; Zheng J; Zheng H; Sheng L; Wynn T; Chang LJ
    Curr Gene Ther; 2019; 19(4):264-273. PubMed ID: 31549954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemophilia gene therapy: ushering in a new treatment paradigm?
    George LA
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):226-233. PubMed ID: 34889378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys.
    Peyvandi F; Garagiola I; Mannucci PM
    Blood Rev; 2021 Sep; 49():100828. PubMed ID: 33810898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adeno-Associated Virus Gene Therapy for Hemophilia.
    Samelson-Jones BJ; George LA
    Annu Rev Med; 2023 Jan; 74():231-247. PubMed ID: 36103998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA.
    Dalla Torre Di Sanguinetto S; Heinonen E; Antonov J; Bolte C
    Ther Innov Regul Sci; 2019 Jan; 53(1):86-94. PubMed ID: 29714594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hemophilia therapy in Italy: what the near future promises.].
    Mannucci PM
    Recenti Prog Med; 2023 May; 114(5):247-249. PubMed ID: 37114604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemophilia clinical gene therapy: brief review.
    Walsh CE; Batt KM
    Transl Res; 2013 Apr; 161(4):307-12. PubMed ID: 23352600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.
    de Wilde S; Coppens DGM; Hoekman J; de Bruin ML; Leufkens HGM; Guchelaar HJ; Meij P
    Drug Discov Today; 2018 Jul; 23(7):1328-1333. PubMed ID: 29574211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.